28102 Search Results


holotype ncib 9203 canada 729 hugh  (ATCC)
90
ATCC holotype ncib 9203 canada 729 hugh
Holotype Ncib 9203 Canada 729 Hugh, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/holotype ncib 9203 canada 729 hugh/product/ATCC
Average 90 stars, based on 1 article reviews
holotype ncib 9203 canada 729 hugh - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdk9 ha  (Addgene inc)
92
Addgene inc cdk9 ha
Cdk9 Ha, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk9 ha/product/Addgene inc
Average 92 stars, based on 1 article reviews
cdk9 ha - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
antibodies against bnip3  (Proteintech)
93
Proteintech antibodies against bnip3
List of primers.
Antibodies Against Bnip3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against bnip3/product/Proteintech
Average 93 stars, based on 1 article reviews
antibodies against bnip3 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


List of primers.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Hypoxia-immune-related microenvironment prognostic signature for osteosarcoma

doi: 10.3389/fcell.2022.974851

Figure Lengend Snippet: List of primers.

Article Snippet: Then, membranes were blocked with 5% w/v skim milk, incubated with primary antibodies against BNIP3 (1:1,000; 68091-1-Ig; Proteintech), SLC38A5 (1:1,000; 28102-1-AP; Proteintech), SLC5A3 (1:1,000; 21628-1-AP; Proteintech), CKMT2 (1:1,000; 13207-1-AP; Proteintech), S100A3 (1:1,000; 12343-1-AP; Proteintech), PGM1 (1:1,000; 15161-1-AP; Proteintech), CXCL11 (1:1,000; MAB672-SP; R&D Systems) and β-actin antibody (1:5,000; NB-600; Sigma) overnight at 4 °C.

Techniques: Sequencing

Validation of seven signature genes at mRNA and protein levels and functional analysis of BNIP3 in vitro . (A) RT-PCR for detecting the expression of seven genes in Saos-2 and 143B osteosarcoma cells and hFOB1.19 cells. (B,D) Western blot and quantification for the expression of the seven genes in Saos-2 cells (under hypoxic or normoxic conditions) and hFOB1.19 cells. (C,E) Western blot and quantification for the expression of the seven genes in 143B cells (under hypoxic or normoxic conditions) and hFOB1.19 cells. (F) RT-PCR for verifying the expression of BNIP3 in Saos-2 and 143B cells following transfection with its specific shRNAs. (G) Western blot for verifying the expression of BNIP3 in Saos-2 and 143B cells following transfection with its specific shRNAs. (H) CCK8 assay of detecting the proliferation ability of Saos-2 and 143B cells after BNIP3 knockdown. (I,J) Colony formation for measuring the proliferation capacity of Saos-2 and 143B cells after BNIP3 knockdown. (K,L) Wound healing assay for detecting the migration ability of Saos-2 and 143B cells after BNIP3 knockdown. * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Hypoxia-immune-related microenvironment prognostic signature for osteosarcoma

doi: 10.3389/fcell.2022.974851

Figure Lengend Snippet: Validation of seven signature genes at mRNA and protein levels and functional analysis of BNIP3 in vitro . (A) RT-PCR for detecting the expression of seven genes in Saos-2 and 143B osteosarcoma cells and hFOB1.19 cells. (B,D) Western blot and quantification for the expression of the seven genes in Saos-2 cells (under hypoxic or normoxic conditions) and hFOB1.19 cells. (C,E) Western blot and quantification for the expression of the seven genes in 143B cells (under hypoxic or normoxic conditions) and hFOB1.19 cells. (F) RT-PCR for verifying the expression of BNIP3 in Saos-2 and 143B cells following transfection with its specific shRNAs. (G) Western blot for verifying the expression of BNIP3 in Saos-2 and 143B cells following transfection with its specific shRNAs. (H) CCK8 assay of detecting the proliferation ability of Saos-2 and 143B cells after BNIP3 knockdown. (I,J) Colony formation for measuring the proliferation capacity of Saos-2 and 143B cells after BNIP3 knockdown. (K,L) Wound healing assay for detecting the migration ability of Saos-2 and 143B cells after BNIP3 knockdown. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Then, membranes were blocked with 5% w/v skim milk, incubated with primary antibodies against BNIP3 (1:1,000; 68091-1-Ig; Proteintech), SLC38A5 (1:1,000; 28102-1-AP; Proteintech), SLC5A3 (1:1,000; 21628-1-AP; Proteintech), CKMT2 (1:1,000; 13207-1-AP; Proteintech), S100A3 (1:1,000; 12343-1-AP; Proteintech), PGM1 (1:1,000; 15161-1-AP; Proteintech), CXCL11 (1:1,000; MAB672-SP; R&D Systems) and β-actin antibody (1:5,000; NB-600; Sigma) overnight at 4 °C.

Techniques: Biomarker Discovery, Functional Assay, In Vitro, Reverse Transcription Polymerase Chain Reaction, Expressing, Western Blot, Transfection, CCK-8 Assay, Knockdown, Wound Healing Assay, Migration